URGN
UroGen Pharma Ltd.
NASDAQ · Healthcare · Biotechnology · US
$43.25
−1.59%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$43.73
From 52W high−14.00%
Volume616384.00
Market cap$2.11B
P/E (TTM)—
P/S (TTM)11.2x
Div yield—
Key dataSep 18, 2026
Open
$43.73
From 52W high
−14.00%
Volume
616384.00
Market cap
$2.11B
ValuationView details →
P/E (Fwd)
35.1x
EV/EBITDA
−31.1x
P/E (TTM)
—
RSI (14)
48.1
MomentumView details →
1D Return
−1.59%
YTD Return
+85.27%
SummaryUpdated Jun 1, 2026
UroGen Pharma Ltd. (NASDAQ:URGN) is a biotechnology company founded in 2004 and based in Princeton, New Jersey, that specializes in developing and commercializing novel treatments for specialty cancers and urothelial diseases. The company went public in May 2017 and has established itself as a focused player in the urological oncology space, with its flagship product <b>JELMYTO</b> already commercialized and a promising pipeline of investigational therapies targeting various forms of bladder and upper tract cancers.
Similar companies
Latest newsMore news →
UroGen Pharma entered into a strategic collaboration and investment agreement with IntraGel to access its biodegradable sustained-release gel platform and expand its oncology pipeline.31d agoUroGen Pharma Ltd. reported its Q2 2026 financial results, with total revenue of $72.5 million and a net loss of $14.4 million.47d ago